Work

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.8010

Authors: Lecia V. Sequist, Jean-Charles Soria, Shirish M. Gadgeel, Heather A. Wakelee, D. Ross Camidge, Andrea Varga, Benjamin J. Solomon, Vassiliki Papadimitrakopoulou, Sarah S. Jaw-Tsai, Lisa Caunt, Paramjit Kaur, Lindsey Rolfe, Andrew R. Allen, Jonathan Wade Goldman

Institutions: Massachusetts General Hospital, Institut Gustave Roussy, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Stanford Cancer Institute, Stanford University, University of Colorado Cancer Center, Peter MacCallum Cancer Centre, The University of Texas MD Anderson Cancer Center, Clovis Oncology (United States), University of California, Los Angeles

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2461360472

Cites:

Cited by: 143

Related to: 10